2-(4-Methoxyphenyl)-α-2-piperidinyl-4-quinolinemethanol Dihydrochloride Property

storage temp. 

room temp

solubility 

H2O: soluble5mg/mL (clear solution)

form 

powder

color 

white to beige

Safety

Hazard Codes 

T

Risk Statements 

25

Safety Statements 

45

RIDADR 

UN 2811 6.1 / PGIII

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H301Toxic if swalloed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

P405Store locked up.

P501Dispose of contents/container to..…

2-(4-Methoxyphenyl)-α-2-piperidinyl-4-quinolinemethanol Dihydrochloride Chemical Properties,Usage,Production

Description

NSC 23925 is a non-substrate inhibitor of P-glycoprotein (P-gp). It selectively reverses multidrug resistance mediated by P-gp over resistance mediated by multidrug resistance-associated protein 1 (MRP1/ABCC1) or breast cancer resistance protein (BCRP/ABCG2). It resensitizes paclitaxel-resistant SKOV3_TR and OVCAR-8_TR cells to paclitaxel . NSC 23925 reverses P-gp efflux, increasing the intracellular accumulation of P-gp substrates, including calcein AM in multidrug-resistant SKOV3_TR and OVCAR-8_TR cells. It prevents paclitaxel-induced overexpression of the P-gp gene MDR1 and P-gp protein level increases in OVCAR-8 cells. It also prevents the development of paclitaxel-induced multidrug resistance in a SKOV3 mouse xenograft model when administered at a dose of 50 mg/kg per day in combination with paclitaxel.

Uses

This molecule shows an ibility to inhibit plasma membrane glycoprotein 1 (Pgp1) in order to counter and even reverse multi-drug resistance (MDR1) in patients diagnosed with cancer.